These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2881941)

  • 21. Tardive dyskinesia in elderly psychiatric patients: a 5-year study.
    Yassa R; Nastase C; Dupont D; Thibeau M
    Am J Psychiatry; 1992 Sep; 149(9):1206-11. PubMed ID: 1354413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prevalence of tardive dyskinesia in geropsychiatric outpatients.
    Chacko RC; Root L; Marmion J; Molinari V; Adams GL
    J Clin Psychiatry; 1985 Feb; 46(2):55-7. PubMed ID: 2857168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study.
    Ganzini L; Heintz RT; Hoffman WF; Casey DE
    Arch Gen Psychiatry; 1991 Mar; 48(3):259-63. PubMed ID: 1671743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ten-year outcome of tardive dyskinesia.
    Gardos G; Casey DE; Cole JO; Perenyi A; Kocsis E; Arato M; Samson JA; Conley C
    Am J Psychiatry; 1994 Jun; 151(6):836-41. PubMed ID: 7910437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of the course of tardive dyskinesia in patients receiving neuroleptics.
    Bergen J; Kitchin R; Berry G
    Biol Psychiatry; 1992 Oct; 32(7):580-94. PubMed ID: 1360260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III.
    van Harten PN; Hoek HW; Matroos GE; Koeter M; Kahn RS
    Am J Psychiatry; 1998 Apr; 155(4):565-7. PubMed ID: 9546009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroleptic-induced tardive dyskinesia among Arab psychotic patients.
    Osman A; Marghalani M; Turkistani IY; Al-Swaf M; Bin Sadiq B
    East Mediterr Health J; 2007; 13(3):625-32. PubMed ID: 17687836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tardive dyskinesia: who is at risk?
    van Os J; Fahy T; Jones P; Harvey I; Toone B; Murray R
    Acta Psychiatr Scand; 1997 Sep; 96(3):206-16. PubMed ID: 9296552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients.
    Go CL; Rosales RL; Caraos RJ; Fernandez HH
    Parkinsonism Relat Disord; 2009 Nov; 15(9):655-9. PubMed ID: 19346155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for drug-induced parkinsonism in tardive dyskinesia patients.
    Hansen TE; Brown WL; Weigel RM; Casey DE
    J Clin Psychiatry; 1988 Apr; 49(4):139-41. PubMed ID: 2895762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tardive dyskinesia in older out-patients: a follow-up study.
    Labbate LA; Lande RG; Jones F; Oleshansky MA
    Acta Psychiatr Scand; 1997 Sep; 96(3):195-8. PubMed ID: 9296550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tardive dyskinesia in outpatients on depot phenothiazine.
    Neehall J
    West Indian Med J; 1989 Dec; 38(4):228-33. PubMed ID: 2576166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changing epidemiology of tardive dyskinesia: an overview.
    Jeste DV; Wyatt RJ
    Am J Psychiatry; 1981 Mar; 138(3):297-309. PubMed ID: 6110344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroleptic-related dyskinesias in children and adolescents.
    Connor DF; Fletcher KE; Wood JS
    J Clin Psychiatry; 2001 Dec; 62(12):967-74. PubMed ID: 11780878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High serum homocysteine levels in young male schizophrenic and schizoaffective patients with tardive parkinsonism and/or tardive dyskinesia.
    Lerner V; Miodownik C; Kaptsan A; Vishne T; Sela BA; Levine J
    J Clin Psychiatry; 2005 Dec; 66(12):1558-63. PubMed ID: 16401157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Race and tardive dyskinesia among outpatients at a CMHC.
    Glazer WM; Morgenstern H; Doucette J
    Hosp Community Psychiatry; 1994 Jan; 45(1):38-42. PubMed ID: 7907310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    Soares-Weiser K; Rathbone J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients.
    Csernansky JG; Kaplan J; Holman CA; Hollister LE
    Psychopharmacology (Berl); 1983; 81(2):115-8. PubMed ID: 6138793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.